Evidence map›Paper›PMID 34262861›Full record

ArticleFrontiers in oncology2021

How the COVID-19 Pandemic Impacted on Integrated Care Pathways for Lung Cancer: The Parallel Experience of a COVID-Spared and a COVID-Dedicated Center.

Giulia Pasello, Jessica Menis, Sara Pilotto, Stefano Frega, Lorenzo Belluomini, Federica Pezzuto, Anna Caliò, Matteo Sepulcri, Nunzia Luna Valentina Cernusco, Marco Schiavon and 12 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 4 institutions in 1 country.

Giulia PaselloMedical Oncology Department, Istituto Oncologico Veneto IRCCS, Padova, Italy.
Jessica MenisMedical Oncology Department, Istituto Oncologico Veneto IRCCS, Padova, Italy.
Sara PilottoSection of Oncology, Department of Medicine, University of Verona School of Medicine and Verona University Hospital Trust, Verona, Italy.
Stefano FregaMedical Oncology Department, Istituto Oncologico Veneto IRCCS, Padova, Italy.
Lorenzo BelluominiSection of Oncology, Department of Medicine, University of Verona School of Medicine and Verona University Hospital Trust, Verona, Italy.
Federica PezzutoUniversity of Padova, Medical School, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, Padova, Italy.
Anna CaliòDepartment of Diagnostics and Public Health, University of Verona School of Medicine and Verona University Hospital Trust, Verona, Italy.
Matteo SepulcriRadiation Oncology Department, Istituto Oncologico Veneto IRCCS, Padova, Italy.
Nunzia Luna Valentina CernuscoRadiation Oncology Department, University of Verona School of Medicine and Verona University Hospital Trust, Verona, Italy.
Marco SchiavonUniversity of Padova, Medical School, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, Padova, Italy.
Maurizio Valentino InfanteCardiovascular and Thoracic Department, University of Verona School of Medicine and Verona University Hospital Trust, Verona, Italy.
Marco DaminUniversity of Padova, Medical School, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, Padova, Italy.
Claudio MichelettoCardiovascular and Thoracic Department, University of Verona School of Medicine and Verona University Hospital Trust, Verona, Italy.
Paola Del BiancoMedical Oncology Department, Istituto Oncologico Veneto IRCCS, Padova, Italy.
Riccardo GiovannettiCardiovascular and Thoracic Department, University of Verona School of Medicine and Verona University Hospital Trust, Verona, Italy.
Laura BonannoMedical Oncology Department, Istituto Oncologico Veneto IRCCS, Padova, Italy.
Umberto FantoniUniversity of Padova, Medical School, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, Padova, Italy.
Valentina GuarneriMedical Oncology Department, Istituto Oncologico Veneto IRCCS, Padova, Italy.
Fiorella CalabreseUniversity of Padova, Medical School, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, Padova, Italy.
Federico ReaUniversity of Padova, Medical School, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, Padova, Italy.
Michele MilellaSection of Oncology, Department of Medicine, University of Verona School of Medicine and Verona University Hospital Trust, Verona, Italy.
PierFranco ConteMedical Oncology Department, Istituto Oncologico Veneto IRCCS, Padova, Italy.
University of Padua · ITUniversity of Verona · ITIstituti di Ricovero e Cura a Carattere Scientifico · ITIstituto Oncologico Veneto · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe COVID-19 pandemic has proved to be a historic challenge for healthcare systems, particularly with regard to cancer patients. So far, very limited data have been presented on the impact on integrated care pathways (ICPs).

methodsWe reviewed the ICPs of lung cancer patients who accessed the Veneto Institute of Oncology (IOV)/University Hospital of Padua (Center 1) and the University Hospital of Verona (Center 2) before and after the COVID-19 pandemic, through sixteen indicators chosen by the members of a multidisciplinary team (MDT).

resultsTwo window periods (March and April 2019 and 2020) were chosen for comparison. Endoscopic diagnostic procedures and major resections for early stage NSCLC patients increased at Center 1, where a priority pathway with dedicated personnel was established for cancer patients. A slight decrease was observed at Center 2 which became part of the COVID unit. Personnel shortage and different processing methods of tumor samples determined a slightly longer time for diagnostic pathway completion at both Centers. Personnel protection strategies led to a MDT reshape on a web basis and to a significant selection of cases to be discussed in both Centers. The optimization of patient access to healthcare units reduced first outpatient oncological visits, patient enrollment in clinical trials, and end-of-life cancer systemic treatments; finally, a higher proportion of hypofractionation was delivered as a radiotherapy approach for early stage and locally advanced NSCLC.

conclusionsBased on the experience of the two Centers, we identified the key steps in ICP that were impacted by the COVID-19 pandemic so as to proactively put in place a robust service provision of thoracic oncology.

Indexed as

COVID-19integrated care pathwaylung cancermultidisciplinary team discussionpandemic

Identifiers

PMID34262861
PMCPMC8273534
OpenAlexW3174322625

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.